Lenvatinib Combined with the PD-1 Inhibitor Camrelizumab in the Treatment of Primary Liver Cancer Caused Hemorrhagic Exfoliative Gastritis
Introduction: Patients with advanced primary liver cancer often lose the opportunity for surgery when they are found, and the treatment options are limited. Lenvatinib, as a multi-target tyrosine kinase inhibitor, has been used as the first-line treatment for advanced liver cancer. Immune checkpoint...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2024-04-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://beta.karger.com/Article/FullText/538006 |
| _version_ | 1827261202096455680 |
|---|---|
| author | Hong Chen Zihua Wang Chunhua Wang |
| author_facet | Hong Chen Zihua Wang Chunhua Wang |
| author_sort | Hong Chen |
| collection | DOAJ |
| description | Introduction: Patients with advanced primary liver cancer often lose the opportunity for surgery when they are found, and the treatment options are limited. Lenvatinib, as a multi-target tyrosine kinase inhibitor, has been used as the first-line treatment for advanced liver cancer. Immune checkpoint inhibitors, such as programmed cell death protein 1 inhibitors, have been successfully used in advanced or metastatic liver cancer. Case Presentation: We report a case of combined lenvatinib and the programmed cell death protein 1 inhibitor camrelizumab in the treatment of primary liver cancer, in which the rare complication of full-thickness gastric mucosa exfoliation occurred. To the best of our knowledge, this is the first report of the side effect of hemorrhagic exfoliative gastritis with the combination of lenvatinib and camrelizumab. Conclusion: Hemorrhagic exfoliative gastritis is an extremely rare clinical complication. Lenvatinib inhibits vascular proliferation and could cause gastrointestinal perforation, which is considered to be the main factor, but whether camrelizumab plays a role in it or only causes gastrointestinal reactions leading to nausea and vomiting, resulting in gastric mucosal exfoliation bleeding, remains to be further explored. |
| first_indexed | 2024-04-24T07:55:28Z |
| format | Article |
| id | doaj.art-dcfad04dd2744b6d91445ed32bc5ea4a |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2025-03-22T02:54:37Z |
| publishDate | 2024-04-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-dcfad04dd2744b6d91445ed32bc5ea4a2024-05-02T06:54:01ZengKarger PublishersCase Reports in Oncology1662-65752024-04-0117154354810.1159/000538006538006Lenvatinib Combined with the PD-1 Inhibitor Camrelizumab in the Treatment of Primary Liver Cancer Caused Hemorrhagic Exfoliative GastritisHong Chen0Zihua Wang1Chunhua Wang2Department of Clinical Pharmacy, Bethune International Peace Hospital, Shijiazhuang, ChinaDepartment of Oncology, Bethune International Peace Hospital, Shijiazhuang, ChinaDepartment of Gastroenterology, Bethune International Peace Hospital, Shijiazhuang, ChinaIntroduction: Patients with advanced primary liver cancer often lose the opportunity for surgery when they are found, and the treatment options are limited. Lenvatinib, as a multi-target tyrosine kinase inhibitor, has been used as the first-line treatment for advanced liver cancer. Immune checkpoint inhibitors, such as programmed cell death protein 1 inhibitors, have been successfully used in advanced or metastatic liver cancer. Case Presentation: We report a case of combined lenvatinib and the programmed cell death protein 1 inhibitor camrelizumab in the treatment of primary liver cancer, in which the rare complication of full-thickness gastric mucosa exfoliation occurred. To the best of our knowledge, this is the first report of the side effect of hemorrhagic exfoliative gastritis with the combination of lenvatinib and camrelizumab. Conclusion: Hemorrhagic exfoliative gastritis is an extremely rare clinical complication. Lenvatinib inhibits vascular proliferation and could cause gastrointestinal perforation, which is considered to be the main factor, but whether camrelizumab plays a role in it or only causes gastrointestinal reactions leading to nausea and vomiting, resulting in gastric mucosal exfoliation bleeding, remains to be further explored.https://beta.karger.com/Article/FullText/538006lenvatinibcamrelizumabhemorrhagic exfoliative gastritisprimary liver cancerprogrammed cell death proteincase report |
| spellingShingle | Hong Chen Zihua Wang Chunhua Wang Lenvatinib Combined with the PD-1 Inhibitor Camrelizumab in the Treatment of Primary Liver Cancer Caused Hemorrhagic Exfoliative Gastritis Case Reports in Oncology lenvatinib camrelizumab hemorrhagic exfoliative gastritis primary liver cancer programmed cell death protein case report |
| title | Lenvatinib Combined with the PD-1 Inhibitor Camrelizumab in the Treatment of Primary Liver Cancer Caused Hemorrhagic Exfoliative Gastritis |
| title_full | Lenvatinib Combined with the PD-1 Inhibitor Camrelizumab in the Treatment of Primary Liver Cancer Caused Hemorrhagic Exfoliative Gastritis |
| title_fullStr | Lenvatinib Combined with the PD-1 Inhibitor Camrelizumab in the Treatment of Primary Liver Cancer Caused Hemorrhagic Exfoliative Gastritis |
| title_full_unstemmed | Lenvatinib Combined with the PD-1 Inhibitor Camrelizumab in the Treatment of Primary Liver Cancer Caused Hemorrhagic Exfoliative Gastritis |
| title_short | Lenvatinib Combined with the PD-1 Inhibitor Camrelizumab in the Treatment of Primary Liver Cancer Caused Hemorrhagic Exfoliative Gastritis |
| title_sort | lenvatinib combined with the pd 1 inhibitor camrelizumab in the treatment of primary liver cancer caused hemorrhagic exfoliative gastritis |
| topic | lenvatinib camrelizumab hemorrhagic exfoliative gastritis primary liver cancer programmed cell death protein case report |
| url | https://beta.karger.com/Article/FullText/538006 |
| work_keys_str_mv | AT hongchen lenvatinibcombinedwiththepd1inhibitorcamrelizumabinthetreatmentofprimarylivercancercausedhemorrhagicexfoliativegastritis AT zihuawang lenvatinibcombinedwiththepd1inhibitorcamrelizumabinthetreatmentofprimarylivercancercausedhemorrhagicexfoliativegastritis AT chunhuawang lenvatinibcombinedwiththepd1inhibitorcamrelizumabinthetreatmentofprimarylivercancercausedhemorrhagicexfoliativegastritis |